Extended administration of the association of zidovudine plus ritonavir during rat pregnancy: Maternal and fetal effects

Clinical and Experimental Obstetrics and Gynecology

Volumn 34, Issue 3, 2007, Pages 175-178

  Pereira Fontes, T M ^a   Santos Simoes R ^a   Martins Oliveira, F H ^b   De Jesus Simoes M ^a   Oliveira Filho, R M ^c   Nakamura, M U ^a   Kulay Jr , L ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Pregnancy; Rat; Ritonavir; Zidovudine

Indexed keywords

RITONAVIR; ZIDOVUDINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FETUS; FETUS DEATH; FETUS RESORPTION; FETUS WEIGHT; HYSTERECTOMY; LAPAROTOMY; MATERNAL MORTALITY; NONHUMAN; PREGNANCY OUTCOME; PRENATAL EXPOSURE; RAT; STEREOMICROSCOPY; WISTAR RAT;

EID: 34948840345     PISSN: 03906663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Brodt H.R., Kamps B.S., Gute P., Knupp B., Staszewski S., Helm E.B.: "Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy". AIDS, 1997, 11, 1731.
2. Bartlett J.A, DeMasi A., Quinn J., Moxham C., Rousseau F.: "Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults". AIDS, 2001, 15, 1369.
3. Cooper E.R., Charurat M., Mofenson L., Hanson C., Clemente Diaz J.P., Hayani K. et al.: "Combination antiretroviral strategies for the treatment of pregnant HIV-1-Infected women and prevention of perinatal HIV-1 transmission". JAIDS, 2002, 29, 484.
4. Gulick R.M., Mellors J.W., Havlir D., Eron J.J., Gonzalez C., McMahon D. et al.: "Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy". N. Engl. J. Med., 1997, 337, 734.
5. Palella Jr. F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A. et al.: "Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection". N. Engl. J. Med., 1998, 338, 853.
6. World Health Organization (WHO). Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants in resource-limited settings: towards universal Access. 2006. [cited 2006 Aug 14]; [92 screens]. Available at URL: http://www.who.int/hiv/pub/guidelines/WHOPMTCT.pdf
7. CDC - Centers for Disease Control and Prevention. HIV/AIDS Surveillance General Epidemiology. 17 July 2000, www.cdc.gov/hiv/graphics/surveill.htm; PHLS AIDS and STD Centre - Communicable Diseases Surveillance Centre and SCIEH. Unpublished quarterly surveillance tables (Table 14). London: PHLS, 2000, 49.
8. World Health Organization (WHO) and Joint United Nations Program on HIV/AIDS (UNAIDS). AIDS epidemic update.[technical inform on line]. Dez 2005. [cited 2006 Aug 14]; [98 screens]. Available at URL: http://www.who.int/hiv/epi- update2005_en.pdf
9. AIDS Info - Current Guidelines. Maternal-child transmission. Safety and toxicity of individual antiretroviral agents in pregnancy. Guidelines (USA) [supplement on line]. 2006. [cited 2005 Jul 22]; [64 screens]. Available at URL: http://aidsinfo.nih.gov/Content-Files/PerinatalGL.pdf
10. Olfert E.D., Cross B.M., McWilliam A.A.: "Canadian Council on Animal Care's Guide to the Care and Use of Experimental Animals", Ottawa Canada, Bradda Printing Services, 1993.
11. Hamilton J.B., Wolfe J.M.: "The effect of male hormone substance upon birth and prenatal development in the rat". Anat. Rec., 1938, 70, 433.
12. Hollander M., Wolfe D.A.: "Nonparametric Statistical Methods". New York, John & Sons, 1973, 503.
13. Silva M., Skolnik P.R., Gorbach S.L., Spielgeman D., Wilson I.B., Fernandez-DiFranco M.G. et al.: "The effect of protease inhibitors on weight and body composition in HIV-infected patients". AIDS, 1998, 12, 1645.
14. Ye J.M., Samaras K., Bonner K.M., Cooney D.J., Kraegen E.W.: "Ritonavir has paradoxical effects on lipid metabolism and insulin sensitivity in rats compared with humans". AIDS, 1998, 12, 2236.
15. Goetzman E.S., Tian L., Nagy T.R., Gower B.A., Schoeb T.R., Elgavish A. et al.: "HIV protease inhibitor ritonavir induces lipoatrophy in male mice". AIDS, 2003, 19, 1141.
16. Valente A.M., Reis A.F., Machado D.M., Succi R.C., Chacra A.R.: "Metabolic alterations in HIV associated lipodystrophy syndrome". Arg. Bras. Endocrinol Metab., 2005, 49, 871.
17. Mamede J.A.V., Simôes M.J., Novo N.F., Juliano Y., Oliveira-Filho R.M., Kulay Jr. L.: "Cronic effects of azidothymide and acyclovir on pregnant rats". Gen. Pharm., 1995, 26, 523.
18. Figueiró Filho E.A., Duarte G., Rosa e Silva A.M., Lopes da Fonseca B.A., Mussi-Pinhata M.M., Quintana SM. et al.: "Effects of antiretroviral drugs on fertility of Wistar rats". Rev. Bras. Ginecol., 2002, 24, 647.
19. Carvalho A.M., Oliveira-Filho R.M., Simões M.J., Amed A.A., Kulay Jr.L.: "Effect of chronic ritonavir administration on pregnant rats and their fetuses". Clin. Exp. Obstet. Gynecol, 2004, 31, 229.
20. Smith J.W., Huisman M.T., Van Tellingen O., Wiltshire H.R., Schinkel A.H.: "Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure". J. Clin. Invest., 1999, 104, 1441.
21. Marzolini C., Rudin C., Decosterd L.A., Telenti A., Schreyer A., Biollaz J. et al.: "Transplacental passage of protease inhibitors at delivery". AIDS, 2002, 16, 889.
22. Chappuy H., Treluyer J.M., Rey E., Dimet J., Fouche M., Firtion G. et al.: "Maternal-fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus". Am. J. Obstet. Gynecol., 2004, 191, 558.
23. Novotna M., Libra A., Kopecky M., Pavek P., Fendrich Z., Semecky V. et al.: "P-glycoprotein expression and distribution in the rat placenta during pregnancy". Reprod. Toxicol., 2004, 18, 785.
24. Marzoline C., Kim R.B.: "Placental transfer of antiretroviral drugs". Clin. Pharmacol. Ther., 2005, 78, 118.
25. Molsa M., Heikkinen T., Hakkola J., Hakala K., Wallerman O., Wadelius M. et al.: "Functional role of P-glycoprotein in the human blood-placental barrier". Clin. Pharmacol. Ther., 2005, 78, 123.
26. Stahlmann R., Chahoud I., Bochert G., Klug S., Kort M., Neubert D.: "Pre-natal toxicity of zidovudine in rats". Teratology, 1988, 38, 28.
27. Litle B.B., Bawdon R.E., Christmas J.T., Sobhi S., Gilstrap L.C.: "Pharmacokinetics of azidothymidine during late pregnancy in Long-Evans rats". Am. J. Obstet. Gynecol., 1989, 161, 732.
28. Greene J.A., Ayers K.M., De Miranda P., Tucker Jr. W.E.: "Postnatal survival in Wistar rats following oral dosage with zidovudine on gestation day 10". Fundam. Appl. Toxicol., 1990, 15, 201.
29. Mirochnick M., Dorenbaum A., Holland D., Cunningham-Schrader B., Cunningham C., Gelber R. et al.: "Concentrations of protease inhibitors in cord blood after in uteri exposure". Pediatr. Infect. Dis. J., 2002, 21, 835.
30. Maulik D., Evans J.F., Ragolia L.: "Fetal growth restriction: pathogenic mechanisms". Clin. Obst. Gynecol., 2006, 49, 219.
31. Cunha A.M., Hagemann C.C., Simoes R.S., Oliveira-Filho R.M., Simoes M.J., Soares J.M. et al.: "Effects of lopinavir-ritonavir combined therapy during the rat pregnancy: Morphological and biochemical aspects". Eur. J. Obstet. Gynecol. Reprod. Biol., 2006, 35, 5910.
32. Huisman M.T., Smith J.W., Wiltshire H.R.M., Hoetelmans R.M., Beijnen J.H., Schinkel A.H.: "P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir". Mol Pharmacol., 2001, 59, 806.
33. Kumar S., Kwei G.Y., Poon G.K., Iliff S.A., Wang Y., Chen Q. et al.: "Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein". J. Pharmacol. Exper. Ther., 2003, 304, 1161.
34. Kageyama M., Namiki H., Fukushima H., Terasaka S., Togawa T., Tanaka A. et al.: "Effect of chronic administration of ritonavir on function of cytochrome P450 3A and P-glycoprotein in rats". Biol. Pharm. Bull., 2005, 28, 130.